1. Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA (1962) Cigarette smoking and coronary heart disease. N Engl J Med 266:796–801
2. Mohanty D, Shetty S, Anil CR, Pathare A, Ghosh K, Yeolekar ME (1998) Factor V Leiden gene mutation in young Indian patients with myocardial infarction. Curr Sci 74:1078–1079
3. Fitzgerald GA, Jates JA, Nowak J (1988) Cigarette smoking and hemostatic function. Am Heart J 115:267–271
4. Nair S, Kulkarni S, Camoens HMT, Ghosh K, Mohanty D (2001) Changes in platelet receptors after smoking—a flow cytometric study. Platelets 12:20–26
5. Freedman JE (2003) CD40-CD40L and platelet function: beyond hemostasis. Circ Res 92:944–946
6. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594
7. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 sig- nalling. Nature 394:200–203
8. Santilli F, Basili S, Ferroni P, Dav ` G (2007) CD40/CD40L system and vascular disease. Intern Emerg Med 2:256–268
9. Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fu- jimura Y, Saito Y (2008) Acute myocardial infarction as a systemic prothrombotic response condition evidenced by increased von Willebrand factor over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 23:301–307
10. Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, Ozay B, Ciloglu F, Yilmaz H, Cam N (2008) Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 23:75–82
11. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Bo- ersma E, Zeiher AM, Simoons ML (2003) Soluble CD40L ligand in acute coronary syndromes. N Engl J Med 348:1104–1111
12. Andr  ́ P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD (2002) CD40L stabilizes arterial thrombi by a b3 integrin-dependent mechanism. Nat Med 8:247–252
13. Andr  ́ P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899
14. Youssef AA, Chang LT, Sheu JJ, Lee FY, Chua S, Yeh KH, Yang CH, Wu CJ, Yip HK (2007) Association between circulating level of CD40 ligand and angiographic morphologic features indicating high-burden thrombus formation in patients with acute myocardial infarction undergoing primary coronary intervention. Circ J 71:1857–1861
15. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KA, Newby DE (2004) Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 109:1926–1929
16. The TIMI Study Group (1985) The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med 312:932–936
17. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, 
18. Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:606